(AMLX) Amylyx Pharmaceuticals - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 1.536m USD | Total Return: 325.9% in 12m

Stock Neuro Treatments, Drug Development, Clinical Trials
Total Rating 51
Safety 76
Buy Signal 0.59
Drug Manufacturers - Specialty & Generic +0.7
Pharmaceuticals -0.1
Market Cap: 1,536m
Avg Trading Vol: 12.4M USD
ATR: 6.50%
Peers RS (IBD): 89.2
Risk 5d forecast
Volatility82.4%
Rel. Tail Risk-13.8%
Reward TTM
Sharpe Ratio2.17
Alpha262.18
Character TTM
Beta0.945
Beta Downside0.840
Drawdowns 3y
Max DD94.84%
CAGR/Max DD-0.23
EPS (Earnings per Share) EPS (Earnings per Share) of AMLX over the last years for every Quarter: "2021-03": null, "2021-06": null, "2021-09": -3.81, "2021-12": -4.15, "2022-03": -0.93, "2022-06": -0.93, "2022-09": -0.92, "2022-12": -0.65, "2023-03": 0.02, "2023-06": 0.31, "2023-09": 0.3, "2023-12": 0.07, "2024-03": -0.12, "2024-06": -0.73, "2024-09": -1.07, "2024-12": -0.55, "2025-03": -0.42, "2025-06": -0.46, "2025-09": -0.37, "2025-12": -0.3, "2026-03": 0,
EPS CAGR: 62.54%
EPS Trend: 9.3%
Last SUE: 2.32
Qual. Beats: 1
Revenue Revenue of AMLX over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0.285, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0.345, 2022-12: 21.885, 2023-03: 71.428, 2023-06: 98.216, 2023-09: 102.693, 2023-12: 108.449, 2024-03: 88.643, 2024-06: -1.023, 2024-09: 0.416, 2024-12: -0.665, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0, 2026-03: null,
Rev. CAGR: 0.00%
Rev. Trend: -32.7%
Last SUE: 0.00
Qual. Beats: 0
Risks
Technicals: volatile
Description: AMLX Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. (AMLX) is a clinical-stage pharmaceutical company focused on neurodegenerative diseases and endocrine conditions.

The companys lead product candidate, avexitide, is in Phase 3 clinical trials for post-bariatric hypoglycemia and congenital hyperinsulinism. This product targets GLP-1 receptors, a common mechanism in metabolic research.

AMLX also develops AMX0035 for Wolfram syndrome (Phase 2) and progressive supranuclear palsy (Phase 2b/3). Additionally, AMX0114 is in Phase 1 for amyotrophic lateral sclerosis. The pharmaceutical sector often involves long development cycles, with high R&D costs and regulatory hurdles.

Further research on ValueRay can provide more in-depth analysis of these clinical trials and market opportunities.

Headlines to Watch Out For
  • Avexitide Phase 3 trial results for hypoglycemia will determine future revenue
  • AMX0035 clinical trial outcomes for Wolfram syndrome impact pipeline value
  • Regulatory approval for new drug candidates drives stock performance
  • Competition in neurodegenerative disease market affects market share
Piotroski VR‑10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.37 > 0.02 and ΔFCF/TA 49.54 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.37 > 3% & CFO -123.3m > Net Income -144.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 14.27 > 1.5 & < 3
Outstanding Shares: last quarter (94.6m) vs 12m ago 37.86% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 45.12%; Δ -45.12% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.90 (Total Current Assets 323.7m - Total Current Liabilities 22.7m) / Total Assets 332.6m
B: -2.26 (Retained Earnings -751.4m / Total Assets 332.6m)
C: -0.55 (EBIT TTM -144.7m / Avg Total Assets 263.1m)
D: -27.42 (Book Value of Equity -751.0m / Total Liabilities 27.4m)
Altman-Z'' Score: -33.92 = D
Beneish M
DSRI: none (Receivables 88.0k/447k, Revenue 0.0/87.4m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.38 (AQ_t 0.01 / AQ_t-1 0.01)
SGI: none (Revenue 0.0 / 87.4m)
TATA: -0.06 (NI -144.7m - CFO -123.3m) / TA 332.6m)
Beneish M-Score: cannot calculate (missing components)
What is the price of AMLX shares? As of April 04, 2026, the stock is trading at USD 13.90 with a total of 1,246,074 shares traded.
Over the past week, the price has changed by +10.33%, over one month by +5.95%, over three months by +31.26% and over the past year by +325.93%.
Is AMLX a buy, sell or hold? Amylyx Pharmaceuticals has received a consensus analysts rating of 4.57. Therefore, it is recommended to buy AMLX.
  • StrongBuy: 5
  • Buy: 1
  • Hold: 1
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the AMLX price?
Wallstreet Target Price 22.8 64%
Analysts Target Price 22.8 64%
AMLX Fundamental Data Overview as of 02 April 2026
P/E Forward = 2.7739
P/S = 0.6625
P/B = 8.4443
Revenue TTM = 0.0 USD
EBIT TTM = -144.7m USD
EBITDA TTM = -144.2m USD
Long Term Debt = 5.96m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.26m USD (from shortTermDebt, last quarter)
Debt = 5.96m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -220.7m USD (from netDebt column, last quarter)
Enterprise Value = 1.23b USD (1.54b + Debt 5.96m - CCE 317.0m)
 Interest Coverage Ratio = unknown (Ebit TTM -144.7m / Interest Expense TTM 0.0)
 EV/FCF = -9.92x (Enterprise Value 1.23b / FCF TTM -123.5m)
FCF Yield = -10.08% (FCF TTM -123.5m / Enterprise Value 1.23b)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 20.1m) / Revenue TTM)
 Tobins Q-Ratio = 3.68 (Enterprise Value 1.23b / Total Assets 332.6m)
 Interest Expense / Debt = 58.02% (Interest Expense 3.46m / Debt 5.96m)
 Taxrate = 21.0% (US default 21%)
NOPAT = -114.3m (EBIT -144.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.27 (Total Current Assets 323.7m / Total Current Liabilities 22.7m)
Debt / Equity = 0.02 (Debt 5.96m / totalStockholderEquity, last quarter 305.3m)
 Debt / EBITDA = 1.53 (negative EBITDA) (Net Debt -220.7m / EBITDA -144.2m)
 Debt / FCF = 1.79 (negative FCF - burning cash) (Net Debt -220.7m / FCF TTM -123.5m)
 Total Stockholder Equity = 251.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -55.00% (Net Income -144.7m / Total Assets 332.6m)
RoE = -57.52% (Net Income TTM -144.7m / Total Stockholder Equity 251.6m)
RoCE = -56.17% (EBIT -144.7m / Capital Employed (Equity 251.6m + L.T.Debt 5.96m))
 RoIC = -45.42% (negative operating profit) (NOPAT -114.3m / Invested Capital 251.6m)
 WACC = 9.27% (E(1.54b)/V(1.54b) * Re(9.31%) + (debt cost/tax rate unavailable))
Discount Rate = 9.31% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 16.90%
 [DCF] Fair Price = unknown (Cash Flow -123.5m)
 EPS Correlation: 9.25 | EPS CAGR: 62.54% | SUE: 2.32 | # QB: 1
Revenue Correlation: -32.67 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.35 | Chg7d=+0.000 | Chg30d=-0.052 | Revisions Net=+0 | Analysts=5
EPS current Year (2026-12-31): EPS=-1.30 | Chg7d=+0.000 | Chg30d=+0.010 | Revisions Net=-3 | Growth EPS=+14.7% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-1.23 | Chg7d=+0.029 | Chg30d=+0.071 | Revisions Net=-1 | Growth EPS=+6.1% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: -0.43 (2 Up / 5 Down within 30d for Current Year)
External Resources
Dataroma Stockcircle